. Their small size allows for rapid penetration of tissues 86 and enables construction of engineered multivalent formats with higher avidity than 87 monoclonal antibodies (mAbs) and other antigen-binding units [8] . Moreover, 88 solubility is notably increased in VHHs due to the presence of hydrophilic amino acid 89 residues in FR2. Hence, these antibody fragments are resistant to aggregation and 90 their monomeric nature is preserved in solution [9] . 91
Amino acid substitutions cause considerable reshaping of the VHH surface [10] 92 resulting in a large structural diversity of VHH paratopes, e.g. cavity, protruding loop 93 and flat surface. Thereby, the binding of epitopes inaccessible to mAbs, such as those 94 located in the active site of enzymes, is enabled [11] . 95
Their small size, variability, stability, avidity and solubility characteristics 96 render VHHs promising tools for immunotherapy. 97
98

Selection and production of VHHs 99
In order to obtain pathogen-specific VHHs for drug development, their generation 100 must be artificially induced in an experimental host. For this purpose, camelids are 101 immunised with a particular antigen isolated from the infectious organism. Peripheral 102 blood (PB) is collected from which PB lymphocytes are prepared by density gradient 103 centrifugation. The cells are lysed and mRNA is isolated. Extracts of mRNA are used as 104 templates for cDNA synthesis by reverse transcription polymerase chain reaction (RT-105 PCR). In a "nested" approach, Ig heavy chains are amplified with gene-specific 106 primers. Reamplification of VHH genes with specialised primer sets that introduce 107 restriction endonuclease (RE) recognition sites at the 5' and 3' ends of the RT 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 VHH and S36-VHH-GOx were ligated into S. cerevisiae expression vectors and 159 produced as described previously [16] . ELISAs demonstrated that the fusion of GOx to 160 S36-VHH had no negative effect on the binding of SA I/II [20] . 161
Therapeutic effects of these VHHs on cariogenesis were further assessed in 162 vivo. For this purpose, the clinical situation in patients with hyposalivation was 163 simulated by a desalivated rat model. In order to establish a basis for cariogenesis, 164 rats received a diet high in sucrose and were repeatedly infected with S. mutans NG8. 165
After three weeks, rats were administered with a single dose of either VHH per day. 166
Both, S36-VHH and S36-VHH-GOx, were found to decrease colonisation with S. 167 mutans and to exert an anticariogenic effect, however, not to statistically significant 168 degrees. Furthermore, no additional therapeutic effect of GOx in the S36-VHH-GOx 169 fusion protein was observed. Its nonappearance was believed to result from heavy 170 hyposalivation, to achieve a bactericidal effect of the SPS. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Furthermore, it was studied whether effector cell response to LPS could be prevented 214 by VHH 5G. LPS was effectively sequestered by VHH 5G inhibiting the release of 215 proinflammatory molecules. In addition, LPS depletion due to immunoprecipitation by 216 anti-LPS VHHs was assessed to be sufficient for the detoxification of solutions 217 contaminated with LPS [32] . 218
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VHHs directed against viruses 269
Treatment of human respiratory syncytial virus infection 270
Human respiratory syncytial virus (RSV) is the main contributor to lower respiratory
Assessment of the binding to the RSV F protein, by surface plasmon resonance 297 analysis, revealed that both ALX-0171 and Nb017 bind its pre-fusion conformation, 298 where the trimeric format exhibited a marked increase in binding affinity. 299
Furthermore, the effect of trimeric formatting on RSV neutralisation capacity was 300 determined by microneutralisation assays. The potency of the trivalent ALX-0171 301 against RSV-A and RSV-B strains was found to be several thousandfold higher than 302 that of the monovalent Nb017. Moreover, a significant increase in potency, as 303 compared to palivizumab, was ascertained. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 detected at minimum levels, but ALX-0171 potency remained unaffected. 316
The in vivo efficacy of ALX-0171 against RSV was studied in cotton rats. ALX-317 0171 was administered at different doses either by nebulisation before or intranasally 318 after RSV challenge. Viral loads in the nose and lungs were significantly reduced for all 319 doses of intranasally administered ALX-0171. Delivered prophylactically via 320 nebulisation, ALX-0171 reduced nasal RSV titres in a dose-dependent matter and in 321 the lungs it completely blocked RSV replication, even at the lowest dose tested (1 mg 322 kg -1 ). ALX-0171 is therefore superior to palivizumab, which had no effect on viral 323 titres at doses lower than 15 mg kg -1 . 324 ALX-0171 is a potential therapeutic VHH that specifically and efficiently binds 325 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
titres. 374
For the generation of PV1 neutralisation escape mutants, mixtures of PV1 and 375 VHH were created. Isolation of resistant viruses failed for PVSP6A and PVSP29F due to 376 complete inhibition of plaque formation. The other three VHHs were unable to 377 neutralise about 100 plaque forming units (PFU), which was consistent with the 378 number of PFU expected for a neutralising mAb [69] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
